About Vivoryon
Vivoryon is a company based in Halle (Germany) founded in 1997.. The company has 15 employees as of December 31, 2024. Vivoryon offers products and services including varoglutamstat. Vivoryon operates in a competitive market with competitors including T3D Therapeutics, Alzheon, Longeveron, Alchemab and Cerecin, among others.
- Headquarter Halle, Germany
- Employees 15 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Vivoryon Therapeutics N.V.
-
Annual Revenue
$0 (USD)100as on Dec 31, 2024
-
Net Profit
$-21.37 M (USD)27.43as on Dec 31, 2024
-
EBITDA
$-21.62 M (USD)28.63as on Dec 31, 2024
-
Latest Funding Round
$5.99 M (USD), Post-IPO
Oct 06, 2025
-
Investors
-
Employee Count
15
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Vivoryon
Vivoryon is a publicly listed company on the EURONEXT with ticker symbol VVY in Netherlands, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Vivoryon
Vivoryon offers a comprehensive portfolio of products and services, including varoglutamstat. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Inhibits enzymes to treat inflammation and neurodegeneration in severe diseases.
Funding Insights of Vivoryon
- Total Funding Total Funding
- Total Rounds 5
- Last Round Post-IPO — $6.0M
-
First Round
First Round
(05 Nov 2015)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2025 | Amount | Post-IPO - Vivoryon | Valuation |
investors |
|
| May, 2023 | Amount | Post-IPO - Vivoryon | Valuation |
investors |
|
| Oct, 2019 | Amount | Post-IPO - Vivoryon | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Vivoryon
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Vivoryon
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Vivoryon Comparisons
Competitors of Vivoryon
Vivoryon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as T3D Therapeutics, Alzheon, Longeveron, Alchemab and Cerecin, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for neurodegenerative diseases, including Alzheimer's, are developed.
|
|
| domain | founded_year | HQ Location |
Oral inhibitors of amyloid aggregation for Alzheimer's treatment are developed.
|
|
| domain | founded_year | HQ Location |
Cellular therapies for aging-related and life-threatening conditions are developed.
|
|
| domain | founded_year | HQ Location |
Developer of antibody based therapeutics to treat cancers, neurodegenerative conditions and infectious diseases
|
|
| domain | founded_year | HQ Location |
Medical foods and drugs for Alzheimer's disease are developed.
|
|
| domain | founded_year | HQ Location |
Genome-scale drug discovery platform is provided for treating multiple diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Vivoryon
Frequently Asked Questions about Vivoryon
When was Vivoryon founded?
Vivoryon was founded in 1997 and raised its 1st funding round 18 years after it was founded.
Where is Vivoryon located?
Vivoryon is headquartered in Halle, Germany. It is registered at Halle, Sachsen-anhalt, Germany.
Who is the current CEO of Vivoryon?
Ulrich Dauer is the current CEO of Vivoryon.
How many employees does Vivoryon have?
As of Dec 31, 2024, the latest employee count at Vivoryon is 15.
What does Vivoryon do?
Vivoryon Therapeutics was founded in 1997 in Halle, Germany, where small molecule inhibitors targeting glutaminyl cyclase enzymes are developed for age-related conditions. The lead candidate, PQ912, is in phase 2a clinical trials for Alzheimers disease and cancer. Additional preclinical candidates, such as PQ1565, address cancer and related disorders by inhibiting key enzymes in disease pathways. Operations focus on biotechnology for therapeutic innovation in neurology and oncology.
Who are the top competitors of Vivoryon?
Vivoryon's top competitors include Alzheon, Longeveron and Alchemab.
What products or services does Vivoryon offer?
Vivoryon offers varoglutamstat.
Is Vivoryon publicly traded?
Yes, Vivoryon is publicly traded on EURONEXT under the ticker symbol VVY.
What is Vivoryon's ticker symbol?
The ticker symbol of Vivoryon is VVY on EURONEXT.